Search research articles
Contact Us
Filters
Showing results (11-20 of 34) with videos related to
Page
of 4
Sort By:
Psychopharmacology Bulletin
|
June 29, 2010
Signal detection and placebo response in schizophrenia: parallels with depression
Craig H Mallinckrodt, Lu Zhang, William R Prucka, et al.
Biological Psychiatry
|
April 20, 2015
Exploratory analysis for a targeted patient population responsive to the metabotropic glutamate 2/3 receptor agonist pomaglumetad methionil in schizophrenia
Bruce J Kinon, Brian A Millen, Lu Zhang, et al.
BMJ (Clinical Research Ed.)
|
March 24, 2011
Impact of reduction in working hours for doctors in training on postgraduate medical education and patients' outcomes: systematic review
S R Moonesinghe, J Lowery, N Shahi, et al.
Therapeutic Innovation & Regulatory Science
|
September 22, 2018
Multipopulation Tailoring Clinical Trials: Design, Analysis, and Inference Considerations
Brian A Millen, Alex Dmitrienko, Sumithra J Mandrekar, et al.
Schizophrenia Research and Treatment
|
April 29, 2014
Pomaglumetad Methionil (LY2140023 Monohydrate) and Aripiprazole in Patients with Schizophrenia: A Phase 3, Multicenter, Double-Blind Comparison
David H Adams, Lu Zhang, Brian A Millen, et al.
Journal of Child and Adolescent Psychopharmacology
|
March 1, 2012
Comparison of long-term (at least 24 weeks) weight gain and metabolic changes between adolescents and adults treated with olanzapine
Ludmila A Kryzhanovskaya, Wen Xu, Brian A Millen, et al.
The Journal of Surgical Research
|
November 15, 2020
Evolving Role of Liver Resection in Selected Patients With Metastatic Breast Cancer
Janelle-Cheri A Millen, Alana Hofmann, Jose Wilson Mesquita-Neto, et al.
Cephalalgia : an International Journal of Headache
|
June 1, 2018
Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial
Vladimir Skljarevski, Manjit Matharu, Brian A Millen, et al.
Vaccine
|
July 26, 2023
Re-evaluation of the risk of venous thromboembolism after COVID-19 vaccination using haematological criteria
Rebecca J Shaw, Andrew J Doyle, Emily A Millen, et al.
Headache
|
November 12, 2019
Rapid Onset of Effect of Galcanezumab for the Prevention of Episodic Migraine: Analysis of the EVOLVE Studies
Holland C Detke, Brian A Millen, Qi Zhang, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 34) with videos related to
Sort By:
Page
of 4
Psychopharmacology Bulletin
|
June 29, 2010
Signal detection and placebo response in schizophrenia: parallels with depression
Craig H Mallinckrodt, Lu Zhang, William R Prucka, et al.
Biological Psychiatry
|
April 20, 2015
Exploratory analysis for a targeted patient population responsive to the metabotropic glutamate 2/3 receptor agonist pomaglumetad methionil in schizophrenia
Bruce J Kinon, Brian A Millen, Lu Zhang, et al.
BMJ (Clinical Research Ed.)
|
March 24, 2011
Impact of reduction in working hours for doctors in training on postgraduate medical education and patients' outcomes: systematic review
S R Moonesinghe, J Lowery, N Shahi, et al.
Therapeutic Innovation & Regulatory Science
|
September 22, 2018
Multipopulation Tailoring Clinical Trials: Design, Analysis, and Inference Considerations
Brian A Millen, Alex Dmitrienko, Sumithra J Mandrekar, et al.
Schizophrenia Research and Treatment
|
April 29, 2014
Pomaglumetad Methionil (LY2140023 Monohydrate) and Aripiprazole in Patients with Schizophrenia: A Phase 3, Multicenter, Double-Blind Comparison
David H Adams, Lu Zhang, Brian A Millen, et al.
Journal of Child and Adolescent Psychopharmacology
|
March 1, 2012
Comparison of long-term (at least 24 weeks) weight gain and metabolic changes between adolescents and adults treated with olanzapine
Ludmila A Kryzhanovskaya, Wen Xu, Brian A Millen, et al.
The Journal of Surgical Research
|
November 15, 2020
Evolving Role of Liver Resection in Selected Patients With Metastatic Breast Cancer
Janelle-Cheri A Millen, Alana Hofmann, Jose Wilson Mesquita-Neto, et al.
Cephalalgia : an International Journal of Headache
|
June 1, 2018
Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial
Vladimir Skljarevski, Manjit Matharu, Brian A Millen, et al.
Vaccine
|
July 26, 2023
Re-evaluation of the risk of venous thromboembolism after COVID-19 vaccination using haematological criteria
Rebecca J Shaw, Andrew J Doyle, Emily A Millen, et al.
Headache
|
November 12, 2019
Rapid Onset of Effect of Galcanezumab for the Prevention of Episodic Migraine: Analysis of the EVOLVE Studies
Holland C Detke, Brian A Millen, Qi Zhang, et al.
Page
of 4